Condition: Advanced Solid Malignancies · Non-small Cell Lung Cancer (NSCLC) · Colorectal Cancer (CRC) · Sponsor: Bristol-Myers Squibb
The purpose of this study is to evaluate the safety, tolerability, and efficacy of BMS-986523 alone and in combination with anti-cancer agents in participants with advanced solid malignancies
This description comes directly from the study's public registry record.
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com · 855-907-3286 · Clinical.Trials@bms.com
First line of the email MUST contain NCT # and Site #.
Always discuss trial participation with your own doctor first.
| Johns Hopkins Hospital | Baltimore, Maryland, United States | Recruiting |
| NEXT Oncology | San Antonio, Texas, United States | Recruiting |
| START Mountain Region | West Valley City, Utah, United States | Recruiting |
| NEXT Virginia | Fairfax, Virginia, United States | Recruiting |
| BC Cancer Vancouver | Vancouver, British Columbia, Canada | Recruiting |
| Princess Margaret Cancer Centre | Toronto, Ontario, Canada | Recruiting |
| Local Institution - 0006 | Badalona, Barcelona [Barcelona], Spain | Not Yet Recruiting |
| Local Institution - 0008 | Hortaleza, Madrid, Spain | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07223047